Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Low rates of endophthalmitis with intravitreal aflibercept in real world Canadian practice - data from the large prospective study PEGASUS.
Michael Peter Fielden, MD, FRCS(C)
On Demand Cases, Courses, and Papers
2019
Short-term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP-CSC): A Placebo-Controlled Clinical Trial
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2018
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Updates from the Field
2025

Category: Diabetic Retinopathy

See more